Filters
clear all
Filters
Topics
Industry
Type
Brand
WorkcompWire Article

Ripple Effect: Potential Impacts of Tariffs and Proposed Medicaid Cuts on Workers’ Comp

Discover how U.S. trade tariffs and proposed Medicaid cuts could reshape workers’ comp costs and care access. Dave Torrence outlines key risks and strategies in WorkCompWire’s "Leaders Speak" article.

Insurance Journal Article

A True Alternative to Opioids for Workers’ Comp? Questions Remain

Enlyte’s Nikki Wilson weighs in on suzetrigine as a potential opioid alternative in workers’ comp. Discover what this breakthrough could mean for pain management and claims strategies.

Auto Casualty Article

The Implications of Trump's Health Care Executive Order for Workers' Compensation and Auto Insurers

4 MIN READ

Explore the immediate effects of President Trump's 2025 health care executive order on workers' compensation and auto insurers, including rising drug costs and supply chain disruptions.

Workers' Comp Article

Ask The Pharmacist: Bird Flu and Its Growing Impact on Public Health

3 MIN READ

Bird flu, or avian influenza, is an emerging public health and industry concern across North America. While the virus primarily affects birds, it can occasionally spread to humans—raising important questions around occupational exposure and public health safety.

Workers' Comp White Paper

From Setback to Comeback: Effective Solutions for Delayed Recovery

1 MIN READ

Learn how to effectively ignite workers' compensation recovery by addressing some of the biggest return-to-work obstacles, including mental health comorbidities, social factors, and delayed intervention. See how data-driven strategies lead to successful claims management and faster employee recovery.

Workers' Comp Article

Ask The Pharmacist: FDA Approval of Non-Opioid Medication for Acute Pain

3 MIN READ

The U.S. Food and Drug Administration (FDA) recently approved Journavx (suzetrigine), a novel non-opioid medication developed by Vertex Pharmaceuticals for the treatment of moderate to severe acute pain in adults. This approval, announced on January 30, 2025, marks a significant milestone in pain management, introducing the first new class of oral medication for acute pain in over two decades.

Claims Journal Article

A True Alternative to Opioids for Workers’ Comp? Questions Remain

Nikki Wilson examines Journavx, a new FDA-approved nonopioid pain medication, and its potential impact on workers' compensation as a safer alternative to opioids for acute pain management.